tiprankstipranks
Advertisement
Advertisement

CBIO Stock Latest News

Crescent Biopharma reports Q1 EPS (70c), consensus (79c)
The FlyCrescent Biopharma reports Q1 EPS (70c), consensus (79c)
17d ago
CBIO
Crescent Biopharma management to meet with Cantor Fitzgerald
PremiumThe Fly
Crescent Biopharma management to meet with Cantor Fitzgerald
1M ago
CBIO
Crescent Biopharma price target lowered to $22 from $25 at H.C. Wainwright
PremiumThe Fly
Crescent Biopharma price target lowered to $22 from $25 at H.C. Wainwright
2M ago
CBIO
Crescent Biopharma reports Q4 EPS ($4.01) vs. ($19.74) last year
PremiumThe Fly
Crescent Biopharma reports Q4 EPS ($4.01) vs. ($19.74) last year
3M ago
CBIO
Crescent Biopharma sees cash runway into 2028
PremiumThe Fly
Crescent Biopharma sees cash runway into 2028
3M ago
CBIO
3 ‘Strong Buy’ Stocks to Buy Now, 2/19/2026, According to Top Analysts
PremiumMarket News3 ‘Strong Buy’ Stocks to Buy Now, 2/19/2026, According to Top Analysts
3M ago
CBIO
CHWY
Crescent Biopharma announces grants of inducement awards
Premium
The Fly
Crescent Biopharma announces grants of inducement awards
3M ago
CBIO
Crescent Biopharma: Fast-Follower Potential of CR-001 and Strategic Partnerships Support Buy Rating and $25 Target
Premium
Ratings
Crescent Biopharma: Fast-Follower Potential of CR-001 and Strategic Partnerships Support Buy Rating and $25 Target
3M ago
CBIO
Crescent Biopharma announces first patient dosed in ASCENT Phase 1/2 trial
PremiumThe Fly
Crescent Biopharma announces first patient dosed in ASCENT Phase 1/2 trial
3M ago
CBIO
Crescent Biopharma initiated with an Overweight at Piper Sandler
PremiumThe Fly
Crescent Biopharma initiated with an Overweight at Piper Sandler
4M ago
CBIO
Crescent Biopharma initiated with a Buy at Guggenheim
PremiumThe Fly
Crescent Biopharma initiated with a Buy at Guggenheim
4M ago
CBIO
SMMT
Crescent Biopharma Advances CR-001 Cancer Trial Into First-in-Human Stage
PremiumCompany Announcements
Crescent Biopharma Advances CR-001 Cancer Trial Into First-in-Human Stage
4M ago
CBIO
Crescent Biopharma files to sell 19.71M shares of common stock for holders
PremiumThe FlyCrescent Biopharma files to sell 19.71M shares of common stock for holders
4M ago
CBIO
Crescent Biopharma: Advancing De-Risked Immuno-Oncology Pipeline and Strategic Partnerships Underscore Undervalued Buy Opportunity
Premium
Ratings
Crescent Biopharma: Advancing De-Risked Immuno-Oncology Pipeline and Strategic Partnerships Underscore Undervalued Buy Opportunity
4M ago
CBIO
Crescent Biopharma announces regulatory clearance of IND applications
Premium
The Fly
Crescent Biopharma announces regulatory clearance of IND applications
4M ago
CBIO
Two new option listings and eighteen option delistings on December 22nd
PremiumThe Fly
Two new option listings and eighteen option delistings on December 22nd
5M ago
QD
EPS
Crescent Biopharma’s Strategic Growth and Competitive Edge Justify Buy Rating
PremiumRatings
Crescent Biopharma’s Strategic Growth and Competitive Edge Justify Buy Rating
5M ago
CBIO
Crescent Biopharma price target raised to $32 from $28 at Stifel
PremiumThe Fly
Crescent Biopharma price target raised to $32 from $28 at Stifel
5M ago
CBIO
Morning News Wrap-Up: Thursday’s Biggest Stock Market Stories!
PremiumMarket News
Morning News Wrap-Up: Thursday’s Biggest Stock Market Stories!
5M ago
V
HD
Why Is Crescent Biopharma Stock (CBIO) Up Today?
PremiumMarket NewsWhy Is Crescent Biopharma Stock (CBIO) Up Today?
5M ago
CBIO
Crescent Biopharma Secures $185M Through Private Placement
Premium
Company Announcements
Crescent Biopharma Secures $185M Through Private Placement
5M ago
8K
CBIO
Crescent Biopharma’s Promising Future: Buy Rating Backed by CR-001’s Clinical Potential and Strong IP Position
Premium
Ratings
Crescent Biopharma’s Promising Future: Buy Rating Backed by CR-001’s Clinical Potential and Strong IP Position
6M ago
CBIO

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >